biotech
Was a Drop in CRISPR Firms’ Stock Warranted?
Was a Drop in CRISPR Firms’ Stock Warranted?
Claire Asher | Jun 7, 2017
A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.
CAR T-Cell Trials Boast Promising Results
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Learning from Iceland’s Model for Genetic Research
Learning from Iceland’s Model for Genetic Research
Catherine Offord | Jun 1, 2017
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Former Head of Genzyme Dies
Former Head of Genzyme Dies
Diana Kwon | May 15, 2017
Henri Termeer helped usher the biotech company into an industry behemoth.
Life Science Leaders Meet at White House
Life Science Leaders Meet at White House
Kerry Grens | May 8, 2017
Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.
Opinion: Preparing for Potential Disasters
Opinion: Preparing for Potential Disasters
Larissa Paschyn | Jan 25, 2017
How to increase the resiliency of biotechnology organizations in the face of emergency risks
Monsanto and Bayer Announce Approval of Massive Merger
Monsanto and Bayer Announce Approval of Massive Merger
Bob Grant | Dec 13, 2016
On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.
Oligonucleotide Therapeutics Near Approval
Oligonucleotide Therapeutics Near Approval
Catherine Offord | Dec 1, 2016
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
Another CRISPR Biotech Goes Public
Another CRISPR Biotech Goes Public
Bob Grant | Sep 12, 2016
CRISPR Therapeutics, the company started by a pioneer of the gene editing technology, plans to raise $90 million from an initial public offering.
That Other CRISPR Patent Dispute
That Other CRISPR Patent Dispute
Kerry Grens | Aug 31, 2016
The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.